View Future GrowthPharmena 과거 순이익 실적과거 기준 점검 0/6Pharmena은 연평균 22.3%의 비율로 수입이 증가해 온 반면, Personal Products 산업은 연평균 13.2%의 비율로 증가했습니다. 매출은 연평균 62.5%의 비율로 감소했습니다.핵심 정보22.31%순이익 성장률22.40%주당순이익(EPS) 성장률Personal Products 산업 성장률36.25%매출 성장률-62.54%자기자본이익률-30.12%순이익률-172.02%다음 순이익 업데이트26 Aug 2026최근 과거 실적 업데이트Reported Earnings • Feb 26Full year 2025 earnings released: zł0.25 loss per share (vs zł0.11 loss in FY 2024)Full year 2025 results: zł0.25 loss per share (further deteriorated from zł0.11 loss in FY 2024). Revenue: zł1.58m (up 488% from FY 2024). Net loss: zł2.77m (loss widened 119% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 23% per year whereas the company’s share price has fallen by 18% per year.Reported Earnings • Dec 03Third quarter 2025 earnings released: zł0.062 loss per share (vs zł0.043 loss in 3Q 2024)Third quarter 2025 results: zł0.062 loss per share (further deteriorated from zł0.043 loss in 3Q 2024). Revenue: zł407.0k (up zł385.0k from 3Q 2024). Net loss: zł690.0k (loss widened 45% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.공고 • Aug 20Pharmena S.A. to Report First Half, 2025 Results on Aug 29, 2025Pharmena S.A. announced that they will report first half, 2025 results on Aug 29, 2025Reported Earnings • Dec 02Third quarter 2024 earnings released: zł0.043 loss per share (vs zł2.71 profit in 3Q 2023)Third quarter 2024 results: zł0.043 loss per share (down from zł2.71 profit in 3Q 2023). Net loss: zł475.0k (down 102% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 29Second quarter 2024 earnings released: zł0.081 loss per share (vs zł0.051 loss in 2Q 2023)Second quarter 2024 results: zł0.081 loss per share (further deteriorated from zł0.051 loss in 2Q 2023). Net loss: zł904.0k (loss widened 59% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.분석 기사 • Jun 04We Think Pharmena's (WSE:PHR) Solid Earnings Are UnderstatedPharmena S.A.'s ( WSE:PHR ) recent earnings report didn't offer any surprises, with the shares unchanged over the last...모든 업데이트 보기Recent updatesNew Risk • Jun 05New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł3.6m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł3.6m free cash flow). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł1.6m revenue, or US$440k). Market cap is less than US$10m (zł35.0m market cap, or US$9.59m).공고 • May 21Pharmena S.A., Annual General Meeting, Jun 25, 2026Pharmena S.A., Annual General Meeting, Jun 25, 2026, at 11:00 Central European Standard Time.New Risk • Mar 02New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: zł35.1m (US$9.67m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł3.3m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł1.6m revenue, or US$435k). Market cap is less than US$10m (zł35.1m market cap, or US$9.67m).Reported Earnings • Feb 26Full year 2025 earnings released: zł0.25 loss per share (vs zł0.11 loss in FY 2024)Full year 2025 results: zł0.25 loss per share (further deteriorated from zł0.11 loss in FY 2024). Revenue: zł1.58m (up 488% from FY 2024). Net loss: zł2.77m (loss widened 119% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 23% per year whereas the company’s share price has fallen by 18% per year.New Risk • Jan 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł2.9m free cash flow). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł1.3m revenue, or US$354k). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (zł36.8m market cap, or US$10.2m).Reported Earnings • Dec 03Third quarter 2025 earnings released: zł0.062 loss per share (vs zł0.043 loss in 3Q 2024)Third quarter 2025 results: zł0.062 loss per share (further deteriorated from zł0.043 loss in 3Q 2024). Revenue: zł407.0k (up zł385.0k from 3Q 2024). Net loss: zł690.0k (loss widened 45% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.공고 • Aug 20Pharmena S.A. to Report First Half, 2025 Results on Aug 29, 2025Pharmena S.A. announced that they will report first half, 2025 results on Aug 29, 2025New Risk • Jul 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł2.7m free cash flow). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł268k revenue, or US$74k). Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Market cap is less than US$100m (zł39.0m market cap, or US$10.8m).New Risk • Jun 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: zł36.0m (US$9.72m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł2.7m free cash flow). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł268k revenue, or US$72k). Market cap is less than US$10m (zł36.0m market cap, or US$9.72m).공고 • May 23Pharmena S.A., Annual General Meeting, Jun 25, 2025Pharmena S.A., Annual General Meeting, Jun 25, 2025.New Risk • May 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł2.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł2.7m free cash flow). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł268k revenue, or US$70k). Minor Risk Market cap is less than US$100m (zł44.4m market cap, or US$11.6m).New Risk • Dec 23New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: zł41.0m (US$10.00m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł308k revenue, or US$75k). Market cap is less than US$10m (zł41.0m market cap, or US$10.00m).Reported Earnings • Dec 02Third quarter 2024 earnings released: zł0.043 loss per share (vs zł2.71 profit in 3Q 2023)Third quarter 2024 results: zł0.043 loss per share (down from zł2.71 profit in 3Q 2023). Net loss: zł475.0k (down 102% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 29Second quarter 2024 earnings released: zł0.081 loss per share (vs zł0.051 loss in 2Q 2023)Second quarter 2024 results: zł0.081 loss per share (further deteriorated from zł0.051 loss in 2Q 2023). Net loss: zł904.0k (loss widened 59% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.분석 기사 • Jun 04We Think Pharmena's (WSE:PHR) Solid Earnings Are UnderstatedPharmena S.A.'s ( WSE:PHR ) recent earnings report didn't offer any surprises, with the shares unchanged over the last...Reported Earnings • May 27First quarter 2024 earnings released: EPS: zł0.021 (vs zł0.014 loss in 1Q 2023)First quarter 2024 results: EPS: zł0.021 (up from zł0.014 loss in 1Q 2023). Net income: zł235.0k (up zł390.0k from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Apr 11Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to zł7.24, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 25x in the Personal Products industry in Europe. Total loss to shareholders of 26% over the past three years.Upcoming Dividend • Apr 02Upcoming dividend of zł0.85 per shareEligible shareholders must have bought the stock before 09 April 2024. Payment date: 24 April 2024. Trailing yield: 10%. Within top quartile of Polish dividend payers (7.6%). Higher than average of industry peers (2.1%).New Risk • Mar 17New minor risk - Dividend sustainabilityThe company has a short dividend paying track record. Less than a year of continuous dividend payments. Dividend yield: 11% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Short dividend paying track record (less than a year of continuous dividend payments). Share price has been volatile over the past 3 months (9.8% average weekly change). Revenue is less than US$5m (zł19m revenue, or US$4.8m). Market cap is less than US$100m (zł88.7m market cap, or US$22.4m).공고 • Mar 09Pharmena S.A., Annual General Meeting, Apr 03, 2024Pharmena S.A., Annual General Meeting, Apr 03, 2024, at 11:00 Central European Standard Time.New Risk • Feb 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.5% average weekly change). Minor Risks Revenue is less than US$5m (zł19m revenue, or US$4.8m). Market cap is less than US$100m (zł82.2m market cap, or US$20.7m).Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to zł8.10, the stock trades at a trailing P/E ratio of 3.2x. Average trailing P/E is 23x in the Personal Products industry in Europe. Total loss to shareholders of 28% over the past three years.공고 • Jan 24+ 2 more updatesPharmena S.A. to Report Q3, 2024 Results on Nov 27, 2024Pharmena S.A. announced that they will report Q3, 2024 results on Nov 27, 2024Valuation Update With 7 Day Price Move • Jan 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to zł7.70, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 27x in the Personal Products industry in Poland. Total loss to shareholders of 18% over the past three years.Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improves as stock rises 20%After last week's 20% share price gain to zł7.10, the stock trades at a trailing P/E ratio of 2.8x. Average trailing P/E is 26x in the Personal Products industry in Poland. Total loss to shareholders of 21% over the past three years.분석 기사 • Dec 04Pharmena's (WSE:PHR) Solid Earnings Are Supported By Other Strong FactorsPharmena S.A.'s ( WSE:PHR ) strong earnings report was rewarded with a positive stock price move. We have done some...Reported Earnings • Nov 29Third quarter 2023 earnings released: EPS: zł2.70 (vs zł0.01 loss in 3Q 2022)Third quarter 2023 results: EPS: zł2.70 (up from zł0.01 loss in 3Q 2022). Net income: zł30.1m (up zł30.2m from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.공고 • May 16Pharmena S.A., Annual General Meeting, Jun 13, 2023Pharmena S.A., Annual General Meeting, Jun 13, 2023, at 11:00 Central European Standard Time.공고 • Jan 20+ 3 more updatesPharmena S.A. to Report Q1, 2023 Results on May 26, 2023Pharmena S.A. announced that they will report Q1, 2023 results on May 26, 2023Reported Earnings • Nov 27Third quarter 2022 earnings released: zł0.01 loss per share (vs zł0.053 loss in 3Q 2021)Third quarter 2022 results: zł0.01 loss per share (improved from zł0.053 loss in 3Q 2021). Revenue: zł4.56m (up 14% from 3Q 2021). Net loss: zł110.0k (loss narrowed 82% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 28Second quarter 2022 earnings released: zł0.041 loss per share (vs zł0.17 loss in 2Q 2021)Second quarter 2022 results: zł0.041 loss per share (up from zł0.17 loss in 2Q 2021). Revenue: zł4.69m (up 35% from 2Q 2021). Net loss: zł462.0k (loss narrowed 76% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Reported Earnings • Jun 01First quarter 2022 earnings released: zł0.015 loss per share (vs zł0.052 loss in 1Q 2021)First quarter 2022 results: zł0.015 loss per share (up from zł0.052 loss in 1Q 2021). Revenue: zł3.63m (up 10.0% from 1Q 2021). Net loss: zł171.0k (loss narrowed 70% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.공고 • May 31Pharmena S.A., Annual General Meeting, Jun 28, 2022Pharmena S.A., Annual General Meeting, Jun 28, 2022, at 11:00 Central European Standard Time.공고 • Feb 01+ 3 more updatesPharmena S.A. to Report Q3, 2022 Results on Nov 25, 2022Pharmena S.A. announced that they will report Q3, 2022 results on Nov 25, 2022Reported Earnings • Nov 28Third quarter 2021 earnings: EPS in line with expectations, revenues disappointThird quarter 2021 results: zł0.053 loss per share (up from zł0.068 loss in 3Q 2020). Revenue: zł4.00m (up 33% from 3Q 2020). Net loss: zł595.0k (loss narrowed 20% from 3Q 2020). Revenue missed analyst estimates by 2.5%. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.Reported Earnings • Jun 03First quarter 2021 earnings released: zł0.052 loss per share (vs zł0.069 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: zł3.30m (up 30% from 1Q 2020). Net loss: zł568.0k (loss narrowed 25% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.Reported Earnings • Apr 15Full year 2020 earnings released: zł0.63 loss per share (vs zł0.94 loss in FY 2019)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: zł9.93m (down 11% from FY 2019). Net loss: zł6.89m (loss narrowed 27% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.공고 • Jan 23+ 3 more updatesPharmena S.A. to Report First Half, 2021 Results on Aug 27, 2021Pharmena S.A. announced that they will report first half, 2021 results on Aug 27, 2021Is New 90 Day High Low • Dec 18New 90-day low: zł8.94The company is down 15% from its price of zł10.50 on 18 September 2020. The Polish market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is down 31% over the same period.Reported Earnings • Nov 28Third quarter 2020 earnings released: zł0.068 loss per shareThe company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2020 results: Revenue: zł3.01m (down 11% from 3Q 2019). Net loss: zł746.0k (loss narrowed 35% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Oct 15New 90-day low: zł9.20The company is down 32% from its price of zł13.45 on 17 July 2020. The Polish market is down 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 36% over the same period.공고 • Oct 11Pharmena S.A. announced that it expects to receive PLN 1.5 million in fundingPharmena S.A. (WSE:PHR) announced a private placement of series F shares at not more than PLN 13.1 per share for gross proceeds of PLN 1,500,000 on October 9, 2020. The transaction may include participation from Pelion SA. The company’s board of directors has approved the transaction. The transaction is subject approval of shareholders, which will held on November 5, 2020.매출 및 비용 세부 내역Pharmena가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이WSE:PHR 매출, 비용 및 순이익 (PLN Millions)날짜매출순이익일반관리비연구개발비31 Mar 262-35031 Dec 252-35030 Sep 251-24030 Jun 251-23031 Mar 251-24031 Dec 240-14030 Sep 240-13030 Jun 240293031 Mar 240294031 Dec 230274030 Sep 230265030 Jun 230-74031 Mar 23-3-63031 Dec 220-54030 Sep 225-56030 Jun 229-38031 Mar 2216-412031 Dec 2115-512030 Sep 2113-713030 Jun 2112-713031 Mar 2111-712031 Dec 2010-712030 Sep 2010-612030 Jun 2010-613031 Mar 2010-1018031 Dec 1911-918030 Sep 1912-817030 Jun 1912-715031 Mar 1913-210031 Dec 181309030 Sep 181309030 Jun 1813-19031 Mar 1814-110031 Dec 1712-211030 Sep 1714-211030 Jun 1716-212031 Mar 1716-112031 Dec 1616-213030 Sep 1616-415030 Jun 1616-415031 Mar 1616-415031 Dec 1517-415030 Sep 1517-3140양질의 수익: PHR 은(는) 현재 수익성이 없습니다.이익 마진 증가: PHR는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: PHR는 수익성이 없지만 지난 5년 동안 연평균 22.3%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 PHR의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: PHR은 수익성이 없어 지난 해 수익 성장률을 Personal Products 업계(3.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: PHR는 현재 수익성이 없으므로 자본 수익률이 음수(-30.12%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHousehold 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/27 17:08종가2026/07/27 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Pharmena S.A.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Adrian KowollikDr. Kalliwoda ResearchAdrian KowollikEast Value Research GmbH
Reported Earnings • Feb 26Full year 2025 earnings released: zł0.25 loss per share (vs zł0.11 loss in FY 2024)Full year 2025 results: zł0.25 loss per share (further deteriorated from zł0.11 loss in FY 2024). Revenue: zł1.58m (up 488% from FY 2024). Net loss: zł2.77m (loss widened 119% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 23% per year whereas the company’s share price has fallen by 18% per year.
Reported Earnings • Dec 03Third quarter 2025 earnings released: zł0.062 loss per share (vs zł0.043 loss in 3Q 2024)Third quarter 2025 results: zł0.062 loss per share (further deteriorated from zł0.043 loss in 3Q 2024). Revenue: zł407.0k (up zł385.0k from 3Q 2024). Net loss: zł690.0k (loss widened 45% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
공고 • Aug 20Pharmena S.A. to Report First Half, 2025 Results on Aug 29, 2025Pharmena S.A. announced that they will report first half, 2025 results on Aug 29, 2025
Reported Earnings • Dec 02Third quarter 2024 earnings released: zł0.043 loss per share (vs zł2.71 profit in 3Q 2023)Third quarter 2024 results: zł0.043 loss per share (down from zł2.71 profit in 3Q 2023). Net loss: zł475.0k (down 102% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 29Second quarter 2024 earnings released: zł0.081 loss per share (vs zł0.051 loss in 2Q 2023)Second quarter 2024 results: zł0.081 loss per share (further deteriorated from zł0.051 loss in 2Q 2023). Net loss: zł904.0k (loss widened 59% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
분석 기사 • Jun 04We Think Pharmena's (WSE:PHR) Solid Earnings Are UnderstatedPharmena S.A.'s ( WSE:PHR ) recent earnings report didn't offer any surprises, with the shares unchanged over the last...
New Risk • Jun 05New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł3.6m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł3.6m free cash flow). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł1.6m revenue, or US$440k). Market cap is less than US$10m (zł35.0m market cap, or US$9.59m).
공고 • May 21Pharmena S.A., Annual General Meeting, Jun 25, 2026Pharmena S.A., Annual General Meeting, Jun 25, 2026, at 11:00 Central European Standard Time.
New Risk • Mar 02New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: zł35.1m (US$9.67m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł3.3m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł1.6m revenue, or US$435k). Market cap is less than US$10m (zł35.1m market cap, or US$9.67m).
Reported Earnings • Feb 26Full year 2025 earnings released: zł0.25 loss per share (vs zł0.11 loss in FY 2024)Full year 2025 results: zł0.25 loss per share (further deteriorated from zł0.11 loss in FY 2024). Revenue: zł1.58m (up 488% from FY 2024). Net loss: zł2.77m (loss widened 119% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 23% per year whereas the company’s share price has fallen by 18% per year.
New Risk • Jan 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł2.9m free cash flow). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł1.3m revenue, or US$354k). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (zł36.8m market cap, or US$10.2m).
Reported Earnings • Dec 03Third quarter 2025 earnings released: zł0.062 loss per share (vs zł0.043 loss in 3Q 2024)Third quarter 2025 results: zł0.062 loss per share (further deteriorated from zł0.043 loss in 3Q 2024). Revenue: zł407.0k (up zł385.0k from 3Q 2024). Net loss: zł690.0k (loss widened 45% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
공고 • Aug 20Pharmena S.A. to Report First Half, 2025 Results on Aug 29, 2025Pharmena S.A. announced that they will report first half, 2025 results on Aug 29, 2025
New Risk • Jul 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł2.7m free cash flow). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł268k revenue, or US$74k). Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Market cap is less than US$100m (zł39.0m market cap, or US$10.8m).
New Risk • Jun 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: zł36.0m (US$9.72m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł2.7m free cash flow). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł268k revenue, or US$72k). Market cap is less than US$10m (zł36.0m market cap, or US$9.72m).
공고 • May 23Pharmena S.A., Annual General Meeting, Jun 25, 2025Pharmena S.A., Annual General Meeting, Jun 25, 2025.
New Risk • May 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł2.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł2.7m free cash flow). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł268k revenue, or US$70k). Minor Risk Market cap is less than US$100m (zł44.4m market cap, or US$11.6m).
New Risk • Dec 23New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: zł41.0m (US$10.00m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł308k revenue, or US$75k). Market cap is less than US$10m (zł41.0m market cap, or US$10.00m).
Reported Earnings • Dec 02Third quarter 2024 earnings released: zł0.043 loss per share (vs zł2.71 profit in 3Q 2023)Third quarter 2024 results: zł0.043 loss per share (down from zł2.71 profit in 3Q 2023). Net loss: zł475.0k (down 102% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 29Second quarter 2024 earnings released: zł0.081 loss per share (vs zł0.051 loss in 2Q 2023)Second quarter 2024 results: zł0.081 loss per share (further deteriorated from zł0.051 loss in 2Q 2023). Net loss: zł904.0k (loss widened 59% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
분석 기사 • Jun 04We Think Pharmena's (WSE:PHR) Solid Earnings Are UnderstatedPharmena S.A.'s ( WSE:PHR ) recent earnings report didn't offer any surprises, with the shares unchanged over the last...
Reported Earnings • May 27First quarter 2024 earnings released: EPS: zł0.021 (vs zł0.014 loss in 1Q 2023)First quarter 2024 results: EPS: zł0.021 (up from zł0.014 loss in 1Q 2023). Net income: zł235.0k (up zł390.0k from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Apr 11Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to zł7.24, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 25x in the Personal Products industry in Europe. Total loss to shareholders of 26% over the past three years.
Upcoming Dividend • Apr 02Upcoming dividend of zł0.85 per shareEligible shareholders must have bought the stock before 09 April 2024. Payment date: 24 April 2024. Trailing yield: 10%. Within top quartile of Polish dividend payers (7.6%). Higher than average of industry peers (2.1%).
New Risk • Mar 17New minor risk - Dividend sustainabilityThe company has a short dividend paying track record. Less than a year of continuous dividend payments. Dividend yield: 11% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Short dividend paying track record (less than a year of continuous dividend payments). Share price has been volatile over the past 3 months (9.8% average weekly change). Revenue is less than US$5m (zł19m revenue, or US$4.8m). Market cap is less than US$100m (zł88.7m market cap, or US$22.4m).
공고 • Mar 09Pharmena S.A., Annual General Meeting, Apr 03, 2024Pharmena S.A., Annual General Meeting, Apr 03, 2024, at 11:00 Central European Standard Time.
New Risk • Feb 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.5% average weekly change). Minor Risks Revenue is less than US$5m (zł19m revenue, or US$4.8m). Market cap is less than US$100m (zł82.2m market cap, or US$20.7m).
Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to zł8.10, the stock trades at a trailing P/E ratio of 3.2x. Average trailing P/E is 23x in the Personal Products industry in Europe. Total loss to shareholders of 28% over the past three years.
공고 • Jan 24+ 2 more updatesPharmena S.A. to Report Q3, 2024 Results on Nov 27, 2024Pharmena S.A. announced that they will report Q3, 2024 results on Nov 27, 2024
Valuation Update With 7 Day Price Move • Jan 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to zł7.70, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 27x in the Personal Products industry in Poland. Total loss to shareholders of 18% over the past three years.
Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improves as stock rises 20%After last week's 20% share price gain to zł7.10, the stock trades at a trailing P/E ratio of 2.8x. Average trailing P/E is 26x in the Personal Products industry in Poland. Total loss to shareholders of 21% over the past three years.
분석 기사 • Dec 04Pharmena's (WSE:PHR) Solid Earnings Are Supported By Other Strong FactorsPharmena S.A.'s ( WSE:PHR ) strong earnings report was rewarded with a positive stock price move. We have done some...
Reported Earnings • Nov 29Third quarter 2023 earnings released: EPS: zł2.70 (vs zł0.01 loss in 3Q 2022)Third quarter 2023 results: EPS: zł2.70 (up from zł0.01 loss in 3Q 2022). Net income: zł30.1m (up zł30.2m from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
공고 • May 16Pharmena S.A., Annual General Meeting, Jun 13, 2023Pharmena S.A., Annual General Meeting, Jun 13, 2023, at 11:00 Central European Standard Time.
공고 • Jan 20+ 3 more updatesPharmena S.A. to Report Q1, 2023 Results on May 26, 2023Pharmena S.A. announced that they will report Q1, 2023 results on May 26, 2023
Reported Earnings • Nov 27Third quarter 2022 earnings released: zł0.01 loss per share (vs zł0.053 loss in 3Q 2021)Third quarter 2022 results: zł0.01 loss per share (improved from zł0.053 loss in 3Q 2021). Revenue: zł4.56m (up 14% from 3Q 2021). Net loss: zł110.0k (loss narrowed 82% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 28Second quarter 2022 earnings released: zł0.041 loss per share (vs zł0.17 loss in 2Q 2021)Second quarter 2022 results: zł0.041 loss per share (up from zł0.17 loss in 2Q 2021). Revenue: zł4.69m (up 35% from 2Q 2021). Net loss: zł462.0k (loss narrowed 76% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Reported Earnings • Jun 01First quarter 2022 earnings released: zł0.015 loss per share (vs zł0.052 loss in 1Q 2021)First quarter 2022 results: zł0.015 loss per share (up from zł0.052 loss in 1Q 2021). Revenue: zł3.63m (up 10.0% from 1Q 2021). Net loss: zł171.0k (loss narrowed 70% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
공고 • May 31Pharmena S.A., Annual General Meeting, Jun 28, 2022Pharmena S.A., Annual General Meeting, Jun 28, 2022, at 11:00 Central European Standard Time.
공고 • Feb 01+ 3 more updatesPharmena S.A. to Report Q3, 2022 Results on Nov 25, 2022Pharmena S.A. announced that they will report Q3, 2022 results on Nov 25, 2022
Reported Earnings • Nov 28Third quarter 2021 earnings: EPS in line with expectations, revenues disappointThird quarter 2021 results: zł0.053 loss per share (up from zł0.068 loss in 3Q 2020). Revenue: zł4.00m (up 33% from 3Q 2020). Net loss: zł595.0k (loss narrowed 20% from 3Q 2020). Revenue missed analyst estimates by 2.5%. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
Reported Earnings • Jun 03First quarter 2021 earnings released: zł0.052 loss per share (vs zł0.069 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: zł3.30m (up 30% from 1Q 2020). Net loss: zł568.0k (loss narrowed 25% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
Reported Earnings • Apr 15Full year 2020 earnings released: zł0.63 loss per share (vs zł0.94 loss in FY 2019)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: zł9.93m (down 11% from FY 2019). Net loss: zł6.89m (loss narrowed 27% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
공고 • Jan 23+ 3 more updatesPharmena S.A. to Report First Half, 2021 Results on Aug 27, 2021Pharmena S.A. announced that they will report first half, 2021 results on Aug 27, 2021
Is New 90 Day High Low • Dec 18New 90-day low: zł8.94The company is down 15% from its price of zł10.50 on 18 September 2020. The Polish market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is down 31% over the same period.
Reported Earnings • Nov 28Third quarter 2020 earnings released: zł0.068 loss per shareThe company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2020 results: Revenue: zł3.01m (down 11% from 3Q 2019). Net loss: zł746.0k (loss narrowed 35% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Oct 15New 90-day low: zł9.20The company is down 32% from its price of zł13.45 on 17 July 2020. The Polish market is down 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 36% over the same period.
공고 • Oct 11Pharmena S.A. announced that it expects to receive PLN 1.5 million in fundingPharmena S.A. (WSE:PHR) announced a private placement of series F shares at not more than PLN 13.1 per share for gross proceeds of PLN 1,500,000 on October 9, 2020. The transaction may include participation from Pelion SA. The company’s board of directors has approved the transaction. The transaction is subject approval of shareholders, which will held on November 5, 2020.